Publication | Closed Access
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, in combination with everolimus in patients (pts) with clear cell and papillary renal cell cancer (RCC)
10
Citations
0
References
2016
Year
UrologyGenitourinary CancerMedicinePharmacologySmall Molecule InhibitorAnti-cancer AgentCancer TreatmentOncologyPhase 1Clear Cell
No additional data available for this publication yet. Check back later!